CL2021000981A1 - Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361) - Google Patents

Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)

Info

Publication number
CL2021000981A1
CL2021000981A1 CL2021000981A CL2021000981A CL2021000981A1 CL 2021000981 A1 CL2021000981 A1 CL 2021000981A1 CL 2021000981 A CL2021000981 A CL 2021000981A CL 2021000981 A CL2021000981 A CL 2021000981A CL 2021000981 A1 CL2021000981 A1 CL 2021000981A1
Authority
CL
Chile
Prior art keywords
peptides
cancers
present
divisional application
peptide combinations
Prior art date
Application number
CL2021000981A
Other languages
English (en)
Inventor
Toni Weinschenk
Jens Fritsche
Colette Song
Harpreet Singh
Andrea Mahr
Oliver Schoor
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1511792.2A external-priority patent/GB201511792D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CL2021000981A1 publication Critical patent/CL2021000981A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Abstract

La presente invención se relaciona con péptidos, proteínas, ácidos nucleicos y células para usar en métodos inmunoterapéuticos. En particular, la presente invención se relaciona con la inmunoterapia de cáncer. La presente invención además se relaciona con epitopes peptídicos de células T asociados a tumor, solos o en combinación con otros péptidos asociados a tumor que por ejemplo pueden servir como ingredientes farmacéuticos activos de composiciones de vacuna que estimulan respuestas inmunológicas antitumorales, a para estimular a células T ex vivo y transferirlas a los pacientes. Los péptidos unidos a las moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tal, también pueden ser blancos de anticuerpos, receptores solubles de células T, y de otras moléculas de unión.
CL2021000981A 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361) CL2021000981A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188870P 2015-07-06 2015-07-06
GBGB1511792.2A GB201511792D0 (en) 2015-07-06 2015-07-06 Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers

Publications (1)

Publication Number Publication Date
CL2021000981A1 true CL2021000981A1 (es) 2021-09-10

Family

ID=56368954

Family Applications (7)

Application Number Title Priority Date Filing Date
CL2017003361A CL2017003361A1 (es) 2015-07-06 2017-12-26 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres
CL2021000982A CL2021000982A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2021000979A CL2021000979A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2021000981A CL2021000981A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2021000980A CL2021000980A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2023000706A CL2023000706A1 (es) 2015-07-06 2023-03-13 Péptidos y sus combinaciones para el uso en inmunoterapia contra el cáncer
CL2023000708A CL2023000708A1 (es) 2015-07-06 2023-03-13 Péptidos y sus combinaciones para el uso en inmunoterapia contra el cáncer

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CL2017003361A CL2017003361A1 (es) 2015-07-06 2017-12-26 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres
CL2021000982A CL2021000982A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2021000979A CL2021000979A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)

Family Applications After (3)

Application Number Title Priority Date Filing Date
CL2021000980A CL2021000980A1 (es) 2015-07-06 2021-04-19 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CL2023000706A CL2023000706A1 (es) 2015-07-06 2023-03-13 Péptidos y sus combinaciones para el uso en inmunoterapia contra el cáncer
CL2023000708A CL2023000708A1 (es) 2015-07-06 2023-03-13 Péptidos y sus combinaciones para el uso en inmunoterapia contra el cáncer

Country Status (33)

Country Link
US (21) US10487132B2 (es)
EP (2) EP4321172A2 (es)
JP (3) JP6944382B2 (es)
KR (1) KR20180026758A (es)
CN (2) CN113880938A (es)
AU (3) AU2016289754B2 (es)
BR (1) BR112017028363A2 (es)
CA (2) CA2991396A1 (es)
CL (7) CL2017003361A1 (es)
CO (1) CO2017012886A2 (es)
CR (3) CR20170579A (es)
DK (1) DK3319985T3 (es)
EA (1) EA201792671A1 (es)
ES (1) ES2841507T3 (es)
HK (1) HK1255542A1 (es)
HR (1) HRP20210076T1 (es)
HU (1) HUE052628T2 (es)
IL (1) IL256303A (es)
LT (1) LT3319985T (es)
MA (1) MA51531A (es)
MD (1) MD3319985T2 (es)
MX (2) MX2017017148A (es)
MY (1) MY188354A (es)
PE (2) PE20231014A1 (es)
PH (1) PH12018500004A1 (es)
PL (1) PL3319985T3 (es)
PT (1) PT3319985T (es)
RS (1) RS61203B1 (es)
SG (1) SG10202001668PA (es)
SI (1) SI3319985T1 (es)
TW (2) TWI776332B (es)
UA (1) UA124411C2 (es)
ZA (1) ZA201707810B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109628591B (zh) * 2018-12-04 2022-04-15 南方医科大学南方医院 用于肺腺癌预后预测的标志物
CN112007167B (zh) * 2020-08-29 2023-01-24 南京中医药大学 蟾酥多肽在作为蟾蜍甾烯促渗剂中的应用
CN112812197B (zh) * 2021-01-11 2022-05-31 中国药科大学 一种兰州百合多糖及其制备方法和应用
CN114057860B (zh) * 2021-11-09 2023-10-20 中国科学技术大学 特定组氨酸甲基化修饰的s100a9蛋白免疫原、多克隆抗体及其制备方法
CN114717191B (zh) * 2022-04-26 2023-06-16 兰州大学第一医院 一株人肝内胆管癌细胞株icc-x3及其应用
CN115322967B (zh) * 2022-06-13 2023-08-08 浙江省人民医院 一种永生化人甲状腺乳头状癌成纤维细胞株及其构建方法和应用
CN114957399B (zh) * 2022-06-29 2023-05-09 湖北工业大学 一种多肽、多肽衍生物及其在制备抗肿瘤药物中的应用
CN116183920B (zh) * 2022-09-22 2023-10-20 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于检测鼻咽癌预后的抗体组合、系统及应用
CN116144772B (zh) * 2022-11-18 2023-08-25 昆明医科大学第一附属医院 一种Hsa_circ_0006117在制备治疗肺腺癌药物中的应用
CN115737619A (zh) * 2022-11-21 2023-03-07 深圳承启生物科技有限公司 一种用于抑制肿瘤的药物靶点、用途及口服药物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JP2530801B2 (ja) 1978-12-22 1996-09-04 バイオゲン インコーポレイテッド 組換えｄｎａ分子
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
GB2294267B (en) 1993-06-03 1996-11-20 Therapeutic Antibodies Inc Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7103198A (en) * 1997-04-21 1998-11-13 Schering Corporation Mammalian cytokines; related reagents and methods
CA2296287A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in prostate
JP5456222B2 (ja) 1998-12-23 2014-03-26 ジェネンテック， インコーポレイテッド Ｉｌ−１関連ポリペプチド
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20040220094A1 (en) 2003-05-01 2004-11-04 Skinner Keith K. Inverse agonist and agonist peptides that stimulate/inhibit hair growth
ES2379805T3 (es) * 2005-07-27 2012-05-03 Oncotherapy Science, Inc. ECT2 como diana terapéutica del cáncer de esófago
DE602005016112D1 (de) * 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
WO2008013934A2 (en) * 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US8034771B2 (en) * 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
JP6008461B2 (ja) * 2007-07-27 2016-10-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 神経細胞性脳腫瘍に対する新規免疫療法
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI776192B (zh) * 2013-08-05 2022-09-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（四）

Also Published As

Publication number Publication date
AU2021200800B2 (en) 2022-08-18
US10487132B2 (en) 2019-11-26
US20200157176A1 (en) 2020-05-21
CL2021000982A1 (es) 2021-09-10
CN107912043B (zh) 2022-02-18
CA2991396A1 (en) 2017-01-12
SG10202001668PA (en) 2020-04-29
US10703795B2 (en) 2020-07-07
MY188354A (en) 2021-12-02
MD3319985T2 (ro) 2021-01-31
CL2021000980A1 (es) 2021-09-10
JP2022020614A (ja) 2022-02-01
US20220098277A1 (en) 2022-03-31
US20220119485A1 (en) 2022-04-21
US10829537B2 (en) 2020-11-10
TW202124430A (zh) 2021-07-01
TW202222825A (zh) 2022-06-16
BR112017028363A2 (pt) 2018-08-28
US20220106379A1 (en) 2022-04-07
MA51531A (fr) 2020-11-11
AU2021200800A1 (en) 2021-03-04
US20210024609A1 (en) 2021-01-28
US11608370B2 (en) 2023-03-21
US20220119484A1 (en) 2022-04-21
CN107912043A (zh) 2018-04-13
US20190315832A1 (en) 2019-10-17
AU2016289754B2 (en) 2021-02-18
JP6944382B2 (ja) 2021-10-06
US20220135646A1 (en) 2022-05-05
CR20170579A (es) 2018-05-25
AU2016289754A1 (en) 2017-11-30
US20220119486A1 (en) 2022-04-21
US11939366B2 (en) 2024-03-26
PH12018500004A1 (en) 2018-07-09
US20220119487A1 (en) 2022-04-21
US11401319B2 (en) 2022-08-02
JP2024041841A (ja) 2024-03-27
US20220098276A1 (en) 2022-03-31
ZA201707810B (en) 2018-11-28
PT3319985T (pt) 2021-01-06
MX2021013003A (es) 2022-01-18
EP3736283A1 (en) 2020-11-11
JP2018519825A (ja) 2018-07-26
PE20231014A1 (es) 2023-07-05
CR20230563A (es) 2024-01-22
US20200010531A1 (en) 2020-01-09
US11359003B2 (en) 2022-06-14
ES2841507T3 (es) 2021-07-08
CR20230562A (es) 2024-01-22
KR20180026758A (ko) 2018-03-13
US20200291088A1 (en) 2020-09-17
US10626162B2 (en) 2020-04-21
PE20180259A1 (es) 2018-02-05
HRP20210076T1 (hr) 2021-05-14
US20210277087A1 (en) 2021-09-09
UA124411C2 (uk) 2021-09-15
US20210277086A1 (en) 2021-09-09
US20220098275A1 (en) 2022-03-31
CN113880938A (zh) 2022-01-04
AU2022205209A1 (en) 2022-08-04
CO2017012886A2 (es) 2018-03-09
CL2017003361A1 (es) 2018-05-04
TWI776332B (zh) 2022-09-01
US11932678B2 (en) 2024-03-19
US20210277088A1 (en) 2021-09-09
RS61203B1 (sr) 2021-01-29
CL2023000708A1 (es) 2023-08-18
US20220112266A1 (en) 2022-04-14
PL3319985T3 (pl) 2021-05-04
CA3221001A1 (en) 2017-01-12
EA201792671A1 (ru) 2018-06-29
DK3319985T3 (da) 2021-01-04
IL256303A (en) 2018-02-28
HUE052628T2 (hu) 2021-05-28
EP4321172A2 (en) 2024-02-14
US20220135648A1 (en) 2022-05-05
US20220106380A1 (en) 2022-04-07
CL2021000979A1 (es) 2021-09-10
SI3319985T1 (sl) 2021-01-29
HK1255542A1 (zh) 2019-08-23
US20220135647A1 (en) 2022-05-05
MX2017017148A (es) 2018-02-23
LT3319985T (lt) 2020-12-28
CL2023000706A1 (es) 2023-08-18

Similar Documents

Publication Publication Date Title
CL2021000980A1 (es) Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CO2017009616A2 (es) Péptidos y combinación de péptidos y andamiajes para inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
AR127117A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
CO2018002202A2 (es) Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de próstata y otros tipos de cáncer
CO2017008902A2 (es) Péptidos y nuevas combinaciones de péptidos para inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer
PE20181164A1 (es) Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer
CR20180460A (es) Tratamiento contra el cáncer de útero
CO2017012891A2 (es) Péptidos y combinaciones de péptidos para la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
CO2018000245A2 (es) Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
CR20190388A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
CL2021000225A1 (es) Inmunoterapia con péptidos restringidos a b*07 y una combinación de péptidos contra el cáncer y métodos relacionados
CR20220115A (es) PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Div. 2017-522)
CO2018002902A2 (es) Péptidos y combinaciones de péptidos para el tratamiento inmunoterapéutico de varios tipos de cáncer
CR20210167A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso de la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
CO2018012294A2 (es) Inmunoterapia contra el melanoma y otros tipos de cáncer
CO2021003404A2 (es) Inmunoterapia con péptidos restringidos a a*01 y una combinación de péptidos contra el cáncer y métodos relacionados
CL2023001324A1 (es) Péptidos, combinaciones, células para inmunoterapia contra cáncer de vejiga y otros cánceres
CR20190094A (es) Nuevos péptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros de cáncer
CL2021001336A1 (es) Inmunoterapia con péptidos restringidos a b*08 y una combinación de péptidos contra el cáncer y métodos relacionados
CL2017002346A1 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
CL2017002766A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cáncer
CO2017003772A2 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CL2021001012A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer (divisional de la solicitud no. 201800780)
AR124242A2 (es) Péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres
AR122217A2 (es) Péptidos y soportes útiles en el tratamiento inmunoterapéutico de varios tipos de cáncer